“I think the take-home point here is that patient-centered care in the form of navigators to help support patients and provide those frequent check ins really appears to help improve adherence to therapy and progression to advanced therapies,” says Ekene Enemchukwu, MD, MPH.
In this video, Ekene Enemchukwu, MD, MPH, discusses the findings and takeaways of the study, “Identifying navigator impact on utilization of onabotulinumtoxinA as a third-line treatment in overactive bladder: A retrospective database study in the United States.” This study was presented at the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction 2022 Winter Meeting. Enemchukwu is a pelvic reconstruction surgeon at Stanford Health Care, and an assistant professor of urology and obstetrics and gynecology at the Stanford University School of Medicine in California.
Optimizing outcomes in sacral neuromodulation for overactive bladder
October 11th 2023These findings may help guide decision-making in the initial testing phase of the [sacral neuromodulation] device prior to permanent implant or explant, according to Bradley Gill, MD, of the Cleveland Clinic.
Optimizing outcomes in sacral neuromodulation for overactive bladder
October 11th 2023These findings may help guide decision-making in the initial testing phase of the [sacral neuromodulation] device prior to permanent implant or explant, according to Bradley Gill, MD, of the Cleveland Clinic.
2 Clarke Drive
Cranbury, NJ 08512